# A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

> **NCT06465446** · PHASE3 · NOT_YET_RECRUITING · sponsor: **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.** · enrollment: 202 (estimated)

## Conditions studied

- Classic Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Tislelizumab
- **BIOLOGICAL:** IMM01
- **DRUG:** Bendamustine
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT06465446
- **Lead sponsor:** ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06
- **Primary completion:** 2026-06
- **Final completion:** 2029-07
- **Target enrollment:** 202 (ESTIMATED)
- **Last updated:** 2024-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06465446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06465446, "A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06465446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*